Anticoagulation continuity in home-based care depends on more than whether tablets are physically present in the home. Safe continuity also depends on whether current dosing instructions are available, INR testing capacity remains intact where required, bleeding-risk education is current, and replacement medication or monitoring supplies can be sourced before the household moves into an unsafe position. In HCBS and LTSS settings, those pathways are vulnerable during severe weather, pharmacy delay, hospital discharge failure, transport disruption, staffing shortage, and multi-day community emergencies that interrupt normal delivery and review routes. Providers that treat anticoagulation as a routine medication refill pathway often identify risk only when doses are missed, INR monitoring is delayed, or new bleeding concerns emerge without an operational response. High-performing organizations therefore govern these pathways within medication, equipment and supply chain continuity and align them directly with continuity of operations planning in HCBS and LTSS. They build inspection-grade systems that identify person-level anticoagulation dependency, track exact reserve coverage across all required components, trigger escalation at explicit thresholds, and evidence every sourcing, handoff, and recovery action through auditable records.
System and oversight expectations
Funder expectation: Medicaid managed care organizations, waiver authorities, and state oversight teams expect providers supporting anticoagulated individuals to demonstrate uninterrupted access to medication supply, monitoring pathways, and clinically appropriate escalation processes, especially where interruption would increase risk of stroke, thrombosis, major bleeding, emergency transport, or avoidable hospitalization.
Regulatory expectation: CMS-aligned medication safety, chronic disease management, and emergency preparedness oversight require providers to evidence person-level continuity planning for anticoagulation pathways, including documented reserve calculations, threshold-based escalation, current dose-plan validity, and reviewable recovery actions after supply failure, delayed monitoring, or disruption events.
Operational Example 1: Building a live anticoagulation reserve register for medication stock, INR-testing pathway status, and current dosing-plan validity
What happens in day-to-day delivery
The Medication Safety Lead requires every service user receiving warfarin, direct oral anticoagulants, or other high-risk anticoagulation regimens to be entered onto a live reserve register within the EHR. Step 1 is completed by the admitting RN, Pharmacist reviewer, or Care Coordinator during intake and scheduled reassessment: anticoagulant name and strength, prescribed dosing schedule including variable-dose plan where applicable, and maximum safe interruption tolerance in hours are recorded in the anticoagulation continuity profile together with prescriber name, most recent dose-change date, and next planned medication review date. Step 2 is completed by the Supplies Coordinator within two working days of pathway confirmation: exact count of in-date anticoagulant tablets or doses currently in the home, exact location and status of current dosing-plan documentation, and INR monitoring route status such as home device, community clinic, or external phlebotomy are entered into the anticoagulation reserve tracker along with test-strip count where a home INR device is used, lancet stock count where relevant, and next confirmed pharmacy delivery or monitoring appointment date.
Step 3 is completed during routine visits by the Nurse or trained Support Worker: exact number of remaining anticoagulant doses available for immediate use, confirmation that the current dosing plan or medication-administration schedule matches the latest prescriber instruction, and confirmation that INR-testing consumables or appointment information remain available and current are documented in the mobile anticoagulation continuity review form before visit closure. Step 4 is completed weekly by the Team Leader for all high-risk anticoagulation cases: households with fewer than the minimum provider threshold of medication coverage days, households with overdue or imminently due INR review where required, and households with unresolved discrepancies between medication stock and documented dosing plan are reviewed in the anticoagulation continuity dashboard and logged in the continuity action register before the weekly operational review closes. Step 5 is completed monthly by the Quality Lead: percentage of anticoagulated households with fully verified reserve records, number of overdue stock validations, and number of unresolved deficits involving medication supply, dosing-plan validity, or INR pathway readiness are reviewed in the governance assurance report.
Why the practice exists (failure mode)
This practice exists because anticoagulation continuity often fails through partial pathway weakness rather than obvious medication absence. A service user may still have tablets in the home, yet the route is already unsafe if the current dose plan is outdated, INR testing cannot occur on time, or stock calculations do not reflect recent dose adjustments. The failure mode is fragmented anticoagulation readiness, where supply status, dosing instructions, and monitoring arrangements are stored across separate notes and no one holds one operational view of whether the full pathway remains safe under disruption. In Medicaid-funded and state-reviewed services, that creates preventable risk because both under-anticoagulation and over-anticoagulation can cause serious harm when continuity controls are incomplete.
What goes wrong if it is absent
Without a live anticoagulation reserve register, providers often discover the problem only when doses are about to run out, an INR review is missed, or a household is following an outdated dose instruction that no longer matches current prescribing. This leads to delayed escalation, inconsistent medication advice, increased bleeding or clotting risk, and avoidable urgent clinical contact. It also weakens audit defensibility because the provider cannot show when reserve coverage became unsafe, whether the active dosing instruction had been verified, or whether action ownership had been assigned before the household entered a high-risk state.
What observable outcome it produces
The observable outcome is stronger visibility of anticoagulation pathway readiness and earlier correction of reserve and monitoring gaps before medication safety is compromised. Providers can evidence this through reduced numbers of households with incomplete reserve records, improved completion of stock and dosing-plan reviews, fewer near-miss incidents involving missed refills or delayed INR checks, and clearer links between anticoagulation risk status and corrective action ownership. Evidence sources include EHR anticoagulation continuity profiles, anticoagulation reserve trackers, mobile review forms, service dashboards, continuity action registers, and governance assurance reports.
Operational Example 2: Activating threshold-based emergency sourcing for anticoagulant medication and urgent monitoring continuity before safe coverage is exhausted
What happens in day-to-day delivery
When reserve coverage reaches the provider’s escalation threshold, the On-Call Manager and Medication Supplies Coordinator activate the emergency sourcing workflow within the same working hour. Step 1 is completed by the discovering staff member, caregiver, or dashboard reviewer: anticoagulant product at risk, exact number of remaining doses or tablets, and risk reason such as delayed refill, lost medication, discharge supply failure, dose increase, or missed pharmacy delivery are recorded in the continuity incident module together with incident timestamp and reporting source. Step 2 is completed by the RN, Pharmacist reviewer, or anticoagulation-trained Clinical Lead: current anticoagulation risk category, maximum safe delay before replacement stock or INR review is required, and interim risk-management instruction such as medication-hold verification, symptom-monitoring frequency, or escalation criteria for bleeding or thrombotic concern are documented in the EHR clinical continuity note together with most recent INR result where relevant, most recent dose administered, and escalation triggers for bruising, hematuria, melena, neurological change, chest pain, or suspected clotting symptoms.
Step 3 is completed by the Medication Supplies Coordinator: pharmacy or anticoagulation service contacted, stock confirmation result for the exact anticoagulant strength and quantity required, and committed dispatch or collection time are entered into the emergency anticoagulation sourcing log with order reference number, call reference time, and insurance or authorization barrier status. Where monitoring continuity is also at risk, the same step records INR appointment rebooking status, home-test kit availability confirmation, and required turnaround time for result review. Step 4 is completed by the Care Coordinator or Logistics Lead: named delivery recipient or pickup collector, verified delivery address or collection point, and estimated handoff time to household or attending staff are documented in the transport coordination tracker together with contingency route if the primary delivery or monitoring plan fails. Step 5 is completed by the receiving Nurse or delegated trained staff member once medication or monitoring access is restored: delivered anticoagulant quantity by strength, confirmation that the active dosing instruction matches the restored supply, and updated number of safe treatment days or next confirmed INR review date are recorded in the anticoagulation verification form within the mobile system and cross-referenced to the sourcing log before the case can be closed.
Why the practice exists (failure mode)
This workflow exists because anticoagulation continuity becomes unsafe before the final dose is used. The failure mode is delayed escalation, where staff know stock is low or monitoring is overdue but do not convert that awareness into a timed sourcing process integrating clinical triage, pharmacy confirmation, monitoring continuity, transport planning, and dose-plan verification. In practice, safe anticoagulation continuity depends on acting at the threshold point, not waiting until the household misses doses or enters a prolonged period without required INR review.
What goes wrong if it is absent
If threshold-based sourcing is absent, providers lose time through repeated untracked pharmacy calls, unclear prioritization of clinically urgent households, and poor coordination between medication and monitoring pathways. Service users may be left with missed doses, outdated dose instructions, delayed INR review, and increased exposure to bleeding or thrombotic events. This also creates weak governance evidence because the provider may show it attempted sourcing, but not that it acted at the correct threshold, verified the active dosing route, or coordinated the pathway through one auditable workflow.
What observable outcome it produces
The observable outcome is faster restoration of medication and monitoring continuity, with fewer incidents progressing from reserve warning to unsafe anticoagulation exposure. Providers can evidence this through reduced threshold-to-dispatch times, reduced numbers of anticoagulated households requiring urgent escalation due to supply or INR pathway failure, and stronger completion of sourcing logs, transport trackers, and verification records. Evidence sources include continuity incident modules, EHR continuity notes, emergency anticoagulation sourcing logs, transport coordination trackers, anticoagulation verification forms, and governance dashboards.
Operational Example 3: Governing post-incident recovery, dose-plan stabilization, and repeat-risk reduction after anticoagulation pathway disruption
What happens in day-to-day delivery
The Quality Manager and Medication Safety Lead jointly manage recovery once immediate continuity has been restored. Step 1 is completed within one working day by the Care Coordinator: root cause category such as pharmacy no-stock event, discharge communication failure, underestimated usage, insurance barrier, missed INR booking, or outdated dosing-plan documentation, together with the incident reference and current reserve restoration status, is entered into the anticoagulation continuity recovery register. Step 2 is completed by the RN, Pharmacist reviewer, or anticoagulation-trained Clinical Lead: whether any missed dose, delayed dose, bleeding concern, thrombotic symptom concern, or unplanned clinical contact occurred, and required follow-up review date are documented in the post-incident anticoagulation review note within the EHR. Step 3 is completed by the Medication Supplies Coordinator: permanent refill route confirmed, replacement status for medication and testing consumables where applicable, and next reserve verification checkpoint date are recorded in the anticoagulation access stabilization tracker together with updated next INR review date and dose-plan replacement status if documentation was reissued.
Step 4 is completed weekly until all corrective actions are closed by the Registered Manager: overdue corrective actions, updated repeat-risk score for the household, and staff or caregiver education completed on stock awareness, bleeding-red-flag escalation, and dose-plan verification are reviewed in the recovery dashboard. Step 5 is completed monthly by the Governance Committee Chair: number of anticoagulation continuity incidents by root cause, percentage of corrective actions completed by deadline, and repeat incidents involving the same pharmacy, monitoring pathway, documentation weakness, or forecasting issue are reviewed in the board assurance report and used to approve policy, scheduling, vendor, or stock-forecasting changes.
Why the practice exists (failure mode)
This recovery workflow exists because one urgent refill or emergency INR arrangement does not mean the anticoagulation pathway is resilient again. The failure mode is false recovery, where the provider resolves the immediate shortage but leaves unresolved the underlying pharmacy problem, documentation weakness, monitoring failure, or caregiver instruction gap that caused the event. Without structured recovery governance, the same service user remains exposed to repeat anticoagulation pathway failure during the next disruption.
What goes wrong if it is absent
Without post-incident recovery and learning controls, providers repeatedly consume nursing, pharmacy liaison, and logistics capacity on preventable anticoagulation continuity incidents. Households lose confidence, unresolved documentation and monitoring issues persist, and governance teams cannot distinguish isolated disruption from repeat system weakness. In inspection or contract review, the provider may show it solved the immediate problem but not that it reduced recurrence risk through measurable corrective action and follow-up.
What observable outcome it produces
The observable outcome is stronger long-term anticoagulation resilience, with fewer repeat incidents, faster reserve restoration, and clearer governance learning from medication and monitoring supply failures. Providers can evidence this through reduced recurrence of anticoagulation continuity incidents, improved corrective action completion rates, and stronger closure of pharmacy, monitoring, documentation, and forecasting deficits after events. Evidence sources include anticoagulation continuity recovery registers, EHR post-incident notes, anticoagulation access stabilization trackers, recovery dashboards, and board assurance reports.
Conclusion
Anticoagulation continuity cannot be protected by counting tablets alone. It requires a formal governance system that tracks the full medication-and-monitoring pathway, including current dosing-plan validity, INR readiness where required, threshold-based sourcing, and post-incident recovery actions. Providers that manage these pathways through inspection-grade reserve registers, sourcing logs, verification records, and recovery controls are better placed to protect medication safety, bleeding-risk management, and service-user stability. In authority-led HCBS and LTSS delivery, anticoagulation continuity is credible only when reserve status, escalation timing, documentation validity, and recovery learning remain visible, timed, and auditable across routine operations and emergency disruption alike.